Latest news with #APGE
Business Insider
12-07-2025
- Business
- Business Insider
Apogee Therapeutics price target raised to $115 from $100 at BTIG
BTIG raised the firm's price target on Apogee Therapeutics (APGE) to $115 from $100 and keeps a Buy rating on the shares. The firm notes that the new EASI-75 watermark for Biologics in Atopic Dermatitis exceeded its expectations and supports a market-leading profile, the analyst tells investors in a research note. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Yahoo
10-07-2025
- Business
- Yahoo
Apogee Therapeutics (APGE) Falls 17%, Positive Trial Results Fail to Impress Investors
Apogee Therapeutics, Inc. (NASDAQ:APGE) is one of the . Apogee Therapeutics fell by 17.32 percent on Monday to end at $39.24 apiece as investors disposed of positions amid the broader market pessimism, shunning positive results from the company's clinical trial for the treatment of eczema. On Monday, Apogee Therapeutics, Inc. (NASDAQ:APGE) said the phase 2 clinical trial of the APG777 antibody met all primary and key secondary endpoints and exceeded trial objectives. At the 16th week of the trial, Apogee Therapeutics, Inc. (NASDAQ:APGE) said that APG777 demonstrated a 66.9-percent improvement in the Eczema Area and Severity Index-75 (EASI-75) score, the highest topline and placebo-adjusted efficacy of any biologic in a global study. A close-up of a biotechnology machine working on an oncology therapy. 'APG777 has the potential to set a new standard of care by offering improved clinical responses with transformational quarterly or better maintenance dosing, benefitting patients, providers, and payers. Today's results bring us closer to that vision, and we believe further de-risks APG777's path to approval,' said Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Michael Henderson. While we acknowledge the potential of APGE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
